Compare RBCAA & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | ARDX |
|---|---|---|
| Founded | 1974 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1998 | 2014 |
| Metric | RBCAA | ARDX |
|---|---|---|
| Price | $72.58 | $6.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $12.95 |
| AVG Volume (30 Days) | 31.7K | ★ 4.1M |
| Earning Date | 01-30-2026 | 02-19-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 24.34 | N/A |
| EPS | ★ 6.44 | N/A |
| Revenue | $378,269,000.00 | ★ $398,234,000.00 |
| Revenue This Year | $3.93 | $22.44 |
| Revenue Next Year | $9.69 | $34.00 |
| P/E Ratio | $11.27 | ★ N/A |
| Revenue Growth | 16.59 | ★ 58.12 |
| 52 Week Low | $56.79 | $3.21 |
| 52 Week High | $78.25 | $8.40 |
| Indicator | RBCAA | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 44.06 |
| Support Level | $70.74 | $6.92 |
| Resistance Level | $75.86 | $7.43 |
| Average True Range (ATR) | 1.71 | 0.33 |
| MACD | -0.17 | -0.14 |
| Stochastic Oscillator | 41.06 | 1.58 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.